21:52 , Jul 13, 2018 |  BioCentury  |  Strategy

Roche’s partnering priority

As James Sabry gets set to lead partnering for all of Roche pharma, his first order of business might be to build out the company’s late-stage pipeline ahead of an impending patent cliff that puts...
19:20 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Imbruvica, Venclexta combo leads to responses with no detectable MRD in Phase II for CLL

AbbVie Inc. (NYSE:ABBV) said 23 of the first 30 evaluable patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in the Phase II CAPTIVATE (PCYC-1142) trial achieved a response with no...
18:19 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

FDA grants regular approval to Venclexta

FDA granted regular approval to Venclexta venetoclax alone or in combination with Rituxan rituximab to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in patients with or without the 17p deletion who have...
21:11 , Jun 8, 2018 |  BC Extra  |  Company News

FDA grants regular approval to Venclexta

FDA granted regular approval to Venclexta venetoclax alone or in combination with Rituxan rituximab to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in patients with or without the 17p deletion who have...
21:49 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

Venclexta plus Rituxan combo meets in Phase III for CLL

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) and AbbVie Inc. (NYSE:ABBV) reported data from the Phase III MURANO trial in 389 patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who had received one...
19:52 , Feb 17, 2017 |  BC Week In Review  |  Company News

Venclyxto sales and marketing update

NICE issued draft guidance recommending against the use of Venclyxto venetoclax from AbbVie to treat chronic lymphocytic leukemia (CLL) in adults. The committee found “substantial shortcomings” in the clinical effectiveness data submitted by AbbVie and...
04:24 , Dec 10, 2016 |  BioCentury  |  Product Development

AML advances

Treatment paradigms in most cancers have followed a predictable if sometimes slow progression from chemotherapy, to agents that target features prevalent among a classically defined cancer type, to personalized approaches targeting features specific to an...
14:16 , Nov 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML); lymphoma; multiple myeloma (MM) In vitro and mouse studies identified an MCL1 inhibitor that could help treat AML, lymphoma and MM. NMR-based fragment screening, chemical synthesis and optimization, and in vitro...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

Venclexta regulatory update

EMA’s CHMP recommended conditional approval of Venclyxto venetoclax from AbbVie as monotherapy to treat chronic lymphocytic leukemia (CLL) in adults. The product would be indicated in patients with chromosome 17p deletions or tumor protein p53...
07:00 , Oct 14, 2016 |  BC Extra  |  Company News

CHMP backs Ocaliva, Venclyxto

EMA's CHMP recommended conditional approval of both Ocaliva obeticholic acid to treat primary biliary cholangitis and Venclyxto venetoclax as monotherapy to treat chronic lymphocytic leukemia (CLL). Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) markets Ocaliva. The committee recommended...